290 related articles for article (PubMed ID: 22252125)
1. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Gerds AT; Gooley TA; Estey EH; Appelbaum FR; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1211-8. PubMed ID: 22252125
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
3. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
4. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
[TBL] [Abstract][Full Text] [Related]
5. Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Woo J; Deeg HJ; Storer B; Yeung C; Fang M; Mielcarek M; Scott BL
Biol Blood Marrow Transplant; 2017 Jan; 23(1):176-179. PubMed ID: 27789363
[TBL] [Abstract][Full Text] [Related]
6. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.
Nishihori T; Perkins J; Mishra A; Komrokji R; Kim J; Kharfan-Dabaja MA; Perez L; Lancet J; Fernandez H; List A; Anasetti C; Field T
Biol Blood Marrow Transplant; 2014 Jun; 20(6):776-80. PubMed ID: 24534108
[TBL] [Abstract][Full Text] [Related]
7. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Gergis U; Wissa U
Curr Hematol Malig Rep; 2010 Jan; 5(1):1-8. PubMed ID: 20425390
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Platzbecker U; Schetelig J; Finke J; Trenschel R; Scott BL; Kobbe G; Schaefer-Eckart K; Bornhäuser M; Itzykson R; Germing U; Beelen D; Ehninger G; Fenaux P; Deeg HJ; Adès L; ; ; ;
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1415-21. PubMed ID: 22579634
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537
[TBL] [Abstract][Full Text] [Related]
10. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
[TBL] [Abstract][Full Text] [Related]
12. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
[TBL] [Abstract][Full Text] [Related]
14. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
15. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
Scott BL; Storer B; Loken MR; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2005 Jan; 11(1):65-73. PubMed ID: 15625546
[TBL] [Abstract][Full Text] [Related]
16. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
17. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.
Kurosawa S; Fukuda T; Tajima K; Saito B; Fuji S; Yokoyama H; Kim SW; Mori S; Tanosaki R; Heike Y; Takaue Y
Am J Hematol; 2009 Dec; 84(12):815-20. PubMed ID: 19899134
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
20. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
